Physician profile
Josef Khalil
NPI 1356403695
$4,001.43
in general payments reported to CMS, 2019-2025
33 companies · $869 in 2025
The $869 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $296 · 2021: $601 · 2022: $566 · 2023: $571 · 2024: $562 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $750.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.80 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $568.38 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $342.90 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $218.97 | 2020-2025 | Zepbound, Mounjaro, Kisunla |
| Abbott Laboratories | $181.32 | 2019-2025 | Freestyle Libre 3, Prodigy, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $165.69 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $130.51 | 2024-2025 | Gemtesa |
| Lucid Diagnostics INC. | $104.95 | 2021 | |
| Optinose US, INC. | $102.47 | 2020-2025 | |
| Amarin Pharma, INC. | $85.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $85.11 | 2019-2020 | |
| Exact Sciences Corporation | $80.90 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $65.23 | 2024-2025 | Veozah, Myrbetriq |
| Cleerly, INC. | $59.10 | 2025 | Cleerly Labs, Cleerly Ischemia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $57.75 | 2019-2025 | General - Pain Management |
| Allergan, INC. | $47.48 | 2019-2020 | |
| Daiichi Sankyo INC. | $43.72 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $36.81 | 2019-2022 | |
| Medtronic, INC. | $36.77 | 2021-2024 | Pipeline |
| Pfizer INC. | $31.20 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $29.34 | 2019-2022 | |
| Edwards Lifesciences Corporation | $25.67 | 2025 | Sapien 3 Ultra Resilia |
| Biohaven Pharmaceutical Holding Company LTD. | $21.80 | 2022 | |
| Inspire Medical Systems, INC. | $21.16 | 2025 | Inspire |
| Linus Health, INC. | $20.41 | 2022 | |
| Amgen INC. | $20.05 | 2024 | Repatha, Otezla |
| Corcept Therapeutics | $15.79 | 2025 | Korlym |
| Horizon Therapeutics Plc | $15.49 | 2022 | |
| Bardy Diagnostics, INC. | $15.17 | 2021 | |
| Abbvie INC. | $14.84 | 2021 | |
| Therapeuticsmd, INC. | $12.94 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josef Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.